ziftomenib
kura oncology
['leukemia', 'myeloid', 'ziftomenib']
the 600-mg dose of ziftomenib monotherapy had a manageable toxicity profile &amp; provided pronounced antileukemic activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia, results from a phase 1/2 trial. #ash22 
Oncology news and insights from leading researchers and cancer centers.